Anzeige
Mehr »
Freitag, 25.07.2025 - Börsentäglich über 12.000 News
Lizenz aktiviert - Kooperation fix: Diese Aktie will jetzt den Milliardenmarkt erobern!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 882807 | ISIN: US92532F1003 | Ticker-Symbol: VX1
Tradegate
24.07.25 | 21:09
402,55 Euro
+0,17 % +0,70
1-Jahres-Chart
VERTEX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
VERTEX PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
400,75403,2024.07.
400,45403,2024.07.

Aktuelle News zur VERTEX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiVertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis7
VERTEX PHARMACEUTICALS Aktie jetzt für 0€ handeln
DiVertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know15
15.07.Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug15
15.07.Vertex and NHS England agree reimbursement for Alyftrek2
15.07.Vertex's triple combination cystic fibrosis therapy Alyftrek recommended by NICE5
15.07.New cystic fibrosis triple from Vertex backed for NHS use2
15.07.Vertex secures NHS England reimbursement deal for Alyftrek cystic fibrosis treatment5
15.07.Vertex Pharmaceuticals Incorporated: Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis422All eligible people with CF in England can now benefit from this medicine - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement...
► Artikel lesen
14.07.Vertex Pharmaceuticals Incorporated: Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain283Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health care improvement company....
► Artikel lesen
09.07.Vertex Pharmaceuticals' cystic fibrosis therapy Alyftrek granted EC approval42
08.07.VRTX price slides 40% as Vertex Protocol phases out native token, abandons Arbitrum18
08.07.Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)?20
03.07.Vertex Presents Durable CRISPR Therapy Benefits In Sickle Cell And Thalassemia578CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals (VRTX), Thursday reported compelling long-term data for its CRISPR/Cas9 gene-edited therapy, PrCASGEVY, at the EHA Congress. In sickle...
► Artikel lesen
02.07.Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek16
02.07.Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold5
01.07.Sodium channel blockers for pain: New opportunities after Vertex's 'watershed' moment13
01.07.Vertex's new cystic fibrosis treatment approved in EU5
01.07.Vertex Pharmaceuticals Incorporated: Vertex Announces European Commission Approval of ALYFTREK, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis371- ALYFTREK(deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene, making it the broadest label for...
► Artikel lesen
01.07.$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today9
27.06.Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug26
Weiter >>
191 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,3,9